Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
AASLD-IDSA - recommended HCV regimens in renal impairment
Product / population
Recommended HCV regimens in renal impairment. This guideline summary is not a complete antiviral treatment algorithm.
Renal method
CKD severity and dialysis in a regimen-selection guideline; not a product-specific dose conversion.
Source revision
Current retrieved guidance page; exact page revision date not established.
Retrieved
2026-09-09
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Product labeling and regimen-level HCV guidance require reconciliation
The retrieved SOVALDI label retains a severe-renal/ESRD limitation while the guideline discusses recommended sofosbuvir-containing regimens in these populations.
What to reconcile: Have HCV pharmacy/specialist review the exact regimen and companion drugs. No blended dose is generated.
AASLD-IDSA HCV Guidance · Recommended HCV regimens in renal impairment. This guideline summary is not a complete antiviral treatment algorithm.
Renal method: CKD severity and dialysis in a regimen-selection guideline; not a product-specific dose conversion. Source date: Current retrieved guidance page; exact page revision date not established. Retrieved: 2026-09-09
Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
AASLD-IDSA advises that recommended direct-acting antiviral regimens need no renal adjustment; ribavirin may require reduction in CKD stages 3-5. The guidance describes use of sofosbuvir-containing regimens in severe kidney disease and dialysis after 2019 labeling changes. This is a regimen-level recommendation, not evidence that every single-agent product label or combination is identical. Preserve the separately retrieved SOVALDI label limitation and obtain HCV specialist/pharmacy adjudication rather than selecting an empiric dose to reconcile the difference.
RDM53-professional-sofosbuvir-sovaldi-1ac91708fd-C1 · Source locator: Recommendations for CKD; Sofosbuvir-Based Regimens.
Source-specific limits
Underlying trials were referenced by the guidance, not independently reanalyzed in this release.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.